Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

China Pharma Holdings (CPHI) EBIT Margin (2016 - 2025)

China Pharma Holdings' EBIT Margin history spans 16 years, with the latest figure at 97.9% for Q4 2025.

  • For Q4 2025, EBIT Margin rose 758.0% year-over-year to 97.9%; the TTM value through Dec 2025 reached 78.16%, up 2317.0%, while the annual FY2025 figure was 78.16%, 2317.0% up from the prior year.
  • EBIT Margin reached 97.9% in Q4 2025 per CPHI's latest filing, down from 83.06% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 48.14% in Q4 2022 to a low of 150.44% in Q2 2024.
  • Average EBIT Margin over 5 years is 47.06%, with a median of 44.95% recorded in 2022.
  • Peak YoY movement for EBIT Margin: crashed -14258bps in 2024, then surged 8687bps in 2025.
  • A 5-year view of EBIT Margin shows it stood at 47.14% in 2021, then rose by 2bps to 48.14% in 2022, then decreased by -23bps to 37.1% in 2023, then crashed by -384bps to 105.47% in 2024, then rose by 7bps to 97.9% in 2025.
  • Per Business Quant, the three most recent readings for CPHI's EBIT Margin are 97.9% (Q4 2025), 83.06% (Q3 2025), and 63.57% (Q2 2025).